These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 17082512)
1. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Aguiar Bujanda D; Bohn Sarmiento U; Cabrera Suárez MA; Aguiar Morales J Ann Oncol; 2007 Mar; 18(3):556-60. PubMed ID: 17082512 [TBL] [Abstract][Full Text] [Related]
2. Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution. La Verde N; Bareggi C; Garassino M; Borgonovo K; Sburlati P; Pedretti D; Bianchi C; Perrone S; Mihali D; Cobelli S; Mantica C; Rizzo A; Farina G Support Care Cancer; 2008 Nov; 16(11):1311-5. PubMed ID: 18663482 [TBL] [Abstract][Full Text] [Related]
3. Osteonecrosis of the jaws in patients with bone metastasis receiving intravenous bisphosphonates. A rising concern. Aguiar Bujanda D; Cabrera Suárez MA; Bohn Sarmiento U; Quintero Pérez S; Aguiar Morales J Clin Transl Oncol; 2006 Dec; 8(12):919-21. PubMed ID: 17169767 [TBL] [Abstract][Full Text] [Related]
4. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620 [TBL] [Abstract][Full Text] [Related]
5. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ripamonti CI; Maniezzo M; Campa T; Fagnoni E; Brunelli C; Saibene G; Bareggi C; Ascani L; Cislaghi E Ann Oncol; 2009 Jan; 20(1):137-45. PubMed ID: 18647964 [TBL] [Abstract][Full Text] [Related]
6. Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis. Bonomi M; Nortilli R; Molino A; Sava T; Santo A; Caldara A; Cetto GL Med Oncol; 2010 Jun; 27(2):224-9. PubMed ID: 19330470 [TBL] [Abstract][Full Text] [Related]
7. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment? Pilanci KN; Alco G; Ordu C; Sarsenov D; Celebi F; Erdogan Z; Agacayak F; Ilgun S; Tecimer C; Demir G; Eralp Y; Okkan S; Ozmen V Medicine (Baltimore); 2015 May; 94(18):e671. PubMed ID: 25950681 [TBL] [Abstract][Full Text] [Related]
8. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738 [TBL] [Abstract][Full Text] [Related]
9. Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. Gabbert TI; Hoffmeister B; Felsenberg D J Cancer Res Clin Oncol; 2015 Apr; 141(4):749-58. PubMed ID: 25319961 [TBL] [Abstract][Full Text] [Related]
10. [Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid]. Calvo-Villas JM; Tapia Torres M; Govantes Rodríguez J; Carreter de Granda E; Sicilia Guillén F Med Clin (Barc); 2006 Oct; 127(15):576-9. PubMed ID: 17153267 [TBL] [Abstract][Full Text] [Related]
11. Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel. Miyazaki H; Nishimatsu H; Kume H; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Ishikawa A; Igawa Y; Hirano Y; Homma Y BJU Int; 2012 Dec; 110(11 Pt B):E520-5. PubMed ID: 22578070 [TBL] [Abstract][Full Text] [Related]
12. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545 [TBL] [Abstract][Full Text] [Related]
13. Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer. Van Poznak CH; Unger JM; Darke AK; Moinpour C; Bagramian RA; Schubert MM; Hansen LK; Floyd JD; Dakhil SR; Lew DL; Wade JL; Fisch MJ; Henry NL; Hershman DL; Gralow J JAMA Oncol; 2021 Feb; 7(2):246-254. PubMed ID: 33331905 [TBL] [Abstract][Full Text] [Related]
14. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. Grbic JT; Black DM; Lyles KW; Reid DM; Orwoll E; McClung M; Bucci-Rechtweg C; Su G J Am Dent Assoc; 2010 Nov; 141(11):1365-70. PubMed ID: 21037195 [TBL] [Abstract][Full Text] [Related]
15. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Dimopoulos MA; Kastritis E; Bamia C; Melakopoulos I; Gika D; Roussou M; Migkou M; Eleftherakis-Papaiakovou E; Christoulas D; Terpos E; Bamias A Ann Oncol; 2009 Jan; 20(1):117-20. PubMed ID: 18689864 [TBL] [Abstract][Full Text] [Related]
16. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years. Guarneri V; Donati S; Nicolini M; Giovannelli S; D'Amico R; Conte PF Oncologist; 2005; 10(10):842-8. PubMed ID: 16314295 [TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis. Ortega C; Montemurro F; Faggiuolo R; Vormola R; Nanni D; Goia F; Gilardino MO; Aglietta M Acta Oncol; 2007; 46(5):664-8. PubMed ID: 17562443 [TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. Kyrgidis A; Vahtsevanos K; Koloutsos G; Andreadis C; Boukovinas I; Teleioudis Z; Patrikidou A; Triaridis S J Clin Oncol; 2008 Oct; 26(28):4634-8. PubMed ID: 18574158 [TBL] [Abstract][Full Text] [Related]
19. A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors. Manfredi M; Mergoni G; Goldoni M; Salvagni S; Merigo E; Meleti M; Vescovi P Med Oral Patol Oral Cir Bucal; 2017 May; 22(3):e342-e348. PubMed ID: 28390132 [TBL] [Abstract][Full Text] [Related]
20. Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid. García Sáenz JA; López Tarruella S; García Paredes B; Rodríguez Lajusticia L; Villalobos L; Díaz Rubio E Med Oral Patol Oral Cir Bucal; 2007 Sep; 12(5):E351-6. PubMed ID: 17767097 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]